When is the next results date for Yatharth Hospit.?

No Upcoming Board Meetings

Has Yatharth Hospit. declared dividend?

No Dividend History Available

Who are the peers of the Yatharth Hospit.?

Yatharth Hospital's peers include Dr Agarwal's Healthcare, Jupiter Life Line, Health.Global, Kovai Medical, Indraprastha Medical, Artemis Medicare, Shalby, Dr Agarwal's Eye, GPT Healthcare, and Jeena Sikho. In terms of performance, Indraprastha Medical leads with a 1-year return of 99.54%, while Yatharth Hospital has a return of 38.67%.

Peers: The peers of Yatharth Hospit. are Dr Agarwal's Hea, Jupiter Life Lin, Health.Global, Kovai Medical, Indrapr.Medical, Artemis Medicare, Shalby, Dr Agarwal's Eye, GPT Healthcare, and Jeena Sikho.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jupiter Life Lin, Indrapr.Medical, and GPT Healthcare, while Good management risk is found at Dr Agarwal's Hea, Kovai Medical, and the rest. Average management risk is noted at Yatharth Hospit., Shalby, and Dr Agarwal's Eye, while Below Average management risk is seen at Health.Global and Artemis Medicare. For Growth, Excellent growth is observed at Jeena Sikho, while Good growth is found at Dr Agarwal's Hea, Yatharth Hospit., Kovai Medical, and Indrapr.Medical, and the rest. Average growth is noted at Dr Agarwal's Eye and the rest, while Below Average growth is seen at Jupiter Life Lin, Health.Global, Artemis Medicare, and Shalby. In terms of Capital Structure, Excellent capital structure is observed at Jupiter Life Lin, Indrapr.Medical, and GPT Healthcare, while Good capital structure is found at Dr Agarwal's Hea, Kovai Medical, and Shalby, and the rest. Average capital structure is noted at Artemis Medicare, while Below Average capital structure is seen at Health.Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Indrapr.Medical at 99.54%, while the peer with the lowest 1-year return is Shalby at -33.71%. Yatharth Hospit.'s 1-year return is 38.67%, which is significantly lower than Indrapr.Medical's but higher than Shalby's. Additionally, the peers with negative six-month returns include Artemis Medicare and Shalby.

Who are in the management team of Yatharth Hospit.?

As of March 2022, the management team of Yatharth Hospital includes Ajay Kumar Tyagi (Chairman & Wholetime Director), Kapil Kumar (Managing Director), Yatharth Tyagi (Whole-time Director), Mukesh Sharma, Sanjeev Upadhyaya, and Promila Bhardwaj (Independent Directors), and Ritesh Mishra (Company Secretary & Compliance Officer). Each member contributes to the company's governance and operations.

As of March 2022, the management team of Yatharth Hospital includes the following members:<BR><BR>1. Ajay Kumar Tyagi - Chairman & Wholetime Director<BR>2. Kapil Kumar - Managing Director<BR>3. Yatharth Tyagi - Whole-time Director<BR>4. Mukesh Sharma - Independent Director<BR>5. Sanjeev Upadhyaya - Independent Director<BR>6. Ritesh Mishra - Company Secretary & Compliance Officer<BR>7. Promila Bhardwaj - Independent Director<BR><BR>Each member plays a crucial role in the governance and operational management of the company.

What does Yatharth Hospit. do?

Yatharth Hospital & Trauma Care Services Ltd is a mid-cap company in the hospital industry, incorporated in 2008 and converted to a public company in 2021. As of March 2025, it reported net sales of ₹2,318 Cr and a net profit of ₹387 Cr, with a market cap of ₹5,952 Cr.

Overview:<BR>Yatharth Hospital & Trauma Care Services Ltd operates in the hospital industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was incorporated as a Private Limited Company in Delhi on February 28, 2008. It converted to a Public Company on November 3, 2021, and changed its name to Yatharth Hospital & Trauma Care Services Limited on November 18, 2021. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 2,318 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 387 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 5,952 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 45.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.31 <BR>Return on Equity: 8.13% <BR>Price to Book: 3.73 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Yatharth Hospit.?

The top shareholders of Yatharth Hospital include promoter Ajay Kumar Tyagi with 30.59%, mutual funds holding 9.42%, foreign institutional investors at 4.45%, and individual investors with 14.87%. The largest public shareholder is Kotak Mahindra Trustee Co Ltd, representing the Kotak Multicap Fund, with 4.36%.

The top shareholders of Yatharth Hospital include the promoters, who hold the majority of the shares. The promoter with the highest holding is Ajay Kumar Tyagi, with a significant stake of 30.59%. Additionally, mutual funds hold 9.42% of the shares through 8 schemes, while foreign institutional investors (FIIs) account for 4.45% with 30 different FIIs involved. The highest public shareholder is Kotak Mahindra Trustee Co Ltd, representing the Kotak Multicap Fund, which holds 4.36%. Individual investors collectively hold 14.87% of the company's shares.

How big is Yatharth Hospit.?

As of 24th July, Yatharth Hospital & Trauma Care Services Ltd has a market capitalization of 6,119.00 Cr, with recent Net Sales of 880.49 Cr and a Net Profit of 130.54 Cr.

As of 24th July, Yatharth Hospital & Trauma Care Services Ltd has a market capitalization of 6,119.00 Cr and is classified as a Mid Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 880.49 Cr and a Net Profit of 130.54 Cr.<BR><BR>The latest annual reporting period for the balance sheet is March 2024, with Shareholder's Funds amounting to 874.32 Cr and Total Assets of 1,009.07 Cr.

Are Yatharth Hospit. latest results good or bad?

Yatharth Hospital's latest results are generally positive, with record net sales and significant growth in profits; however, concerns about slower debt collection and the sustainability of non-operating income suggest a cautious outlook, leading to a 'Hold' rating from MarketsMOJO.

Yatharth Hospital & Trauma Care Services has reported strong financial results for the quarter ending June 2025, indicating a generally positive performance. The company achieved record net sales of Rs 257.77 crore, reflecting an 11.21% growth compared to the previous quarter. Operating profit also increased to Rs 64.49 crore, showcasing improved operational efficiency.<BR><BR>Profit Before Tax (PBT) rose by 27% to Rs 49.38 crore, while Profit After Tax (PAT) grew by 28.8% to Rs 42.04 crore. The earnings per share (EPS) reached Rs 4.36, which is a positive sign for shareholders.<BR><BR>However, there are some challenges to consider. The Debtors Turnover Ratio has decreased to 2.66 times, suggesting a slower pace in settling debts, which could be a concern for cash flow management. Additionally, while non-operating income has increased to Rs 9.31 crore, its sustainability remains uncertain.<BR><BR>Overall, while the financial performance shows strong growth in key areas, the challenges with debt collection and the sustainability of non-operating income may temper the outlook. The stock is currently rated as 'Hold' by MarketsMOJO, indicating a cautious approach moving forward.

Is Yatharth Hospit. overvalued or undervalued?

As of October 8, 2025, Yatharth Hospital is considered very expensive and overvalued, with a PE ratio of 56.35, an EV to EBITDA of 32.50, and a Price to Book Value of 4.99, despite having a lower PE ratio than peers like Max Healthcare and Fortis Healthcare, while significantly outperforming the Sensex with a year-to-date return of 46.93%.

As of 8 October 2025, the valuation grade for Yatharth Hospital has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 56.35, an EV to EBITDA of 32.50, and a Price to Book Value of 4.99, all of which suggest a high valuation relative to earnings and book value.<BR><BR>In comparison to its peers, Yatharth Hospital's PE ratio is lower than that of Max Healthcare at 92.31 and Fortis Healthcare at 86.26, both of which are also categorized as very expensive. However, it is notably higher than Narayana Hrudaya, which has a PE of 46.14 and is classified as expensive. The recent stock performance has outpaced the Sensex, with a year-to-date return of 46.93% compared to the Sensex's 4.65%, reinforcing the notion that the stock is currently overvalued in the market.

Is Yatharth Hospit. technically bullish or bearish?

As of November 3, 2025, Yatharth Hospital's technical trend is mildly bullish, supported by a bullish MACD and moving averages, though caution is advised due to a mildly bearish KST and lack of momentum in the RSI.

As of 3 November 2025, the technical trend for Yatharth Hospital has changed from bullish to mildly bullish. The weekly MACD remains bullish, supported by bullish signals from the Bollinger Bands on both weekly and monthly time frames. The daily moving averages also indicate a bullish stance. However, the KST on a weekly basis is mildly bearish, suggesting some caution. The RSI shows no signal on both weekly and monthly charts, indicating a lack of momentum. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some mixed signals from other indicators.

How has been the historical performance of Yatharth Hospit.?

Yatharth Hospital has shown significant growth from March 2022 to March 2025, with net sales increasing from 400.94 crore to 880.49 crore, and profit after tax rising from 44.16 crore to 130.55 crore, alongside a substantial improvement in total assets and cash flow. Overall, the hospital has demonstrated robust revenue and profitability growth during this period.

Answer:<BR>The historical performance of Yatharth Hospital shows significant growth in various financial metrics over the past few years.<BR><BR>Breakdown:<BR>Yatharth Hospital's net sales have increased from 400.94 crore in March 2022 to 880.49 crore in March 2025, reflecting a strong upward trend. Total operating income has followed a similar trajectory, rising from 400.94 crore in March 2022 to 880.49 crore in March 2025. The total expenditure, excluding depreciation, also grew from 290.13 crore in March 2022 to 660.30 crore in March 2025, indicating increased operational costs. Operating profit (PBDIT) has seen a notable increase, climbing from 110.81 crore in March 2022 to 236.37 crore in March 2025. Profit before tax rose from 63.11 crore in March 2022 to 171.74 crore in March 2025, while profit after tax increased from 44.16 crore to 130.55 crore in the same period. The company's total assets have surged from 420.57 crore in March 2022 to 1,713.06 crore in March 2025, with total liabilities also rising from 420.57 crore to 1,713.06 crore. Cash flow from operating activities improved significantly, moving from 59 crore in March 2022 to 149 crore in March 2025, contributing to a net cash inflow of 248 crore in March 2025, up from 6 crore in March 2022. Overall, Yatharth Hospital has demonstrated robust growth in revenue, profitability, and asset base over the past few years.

Should I buy, sell or hold Yatharth Hospit.?

Which are the latest news on Yatharth Hospit.?

Why is Yatharth Hospit. falling/rising?

As of 18-Dec, Yatharth Hospital & Trauma Care Services Ltd's stock price is at 671.85, down 0.08%. The stock has been declining recently, losing 4.07% over four days and showing weakness in moving averages, despite strong financial performance in previous quarters.

As of 18-Dec, Yatharth Hospital & Trauma Care Services Ltd's stock price is falling, currently at 671.85, which reflects a decrease of 0.55 (-0.08%). The stock has been on a downward trend, having lost 4.07% over the last four days. This decline is further evidenced by the stock's performance over the past week and month, where it has decreased by 3.27% and 13.64%, respectively, while the benchmark Sensex has only fallen by 0.40% and 0.23% in the same periods.<BR><BR>Additionally, the stock's moving averages indicate a concerning trend, as it is currently lower than the 5-day, 20-day, 50-day, and 100-day moving averages, despite being above the 200-day moving average. This suggests a short-term weakness in the stock's performance. Investor participation has also declined, with delivery volume dropping by 5.53% compared to the 5-day average, indicating reduced trading interest.<BR><BR>While the company has demonstrated strong financial performance over the past quarters, including positive results for nine consecutive quarters and significant growth in operating cash flow and net sales, the recent stock price movement reflects a negative sentiment among investors, leading to the current decline.